AmeriPath
AmeriPath is a wholly-owned subsidiary of Quest Diagnostics and a national anatomic pathology provider, employing over 450 board-certified pathologists across 21+ practice locations in 16 states to deliver surgical pathology, cytopathology, dermatopathology, hematopathology, and molecular diagnostics to hospitals, ambulatory surgery centers, physician offices, and health plans.
- Company typePrivate
- Founded1996
- HeadquartersPalm Beach Gardens, United States
- Headcount5,001–10,000
- GTM typeB2B
- OfferingServices
AmeriPath firmographics
Firmographics- Name
- AmeriPath
- Legal name
- AmeriPath
- Website
- https://ameripath.com
- Company type
- Private
- Founded year
- 1996
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- AmeriPath is a wholly-owned subsidiary of Quest Diagnostics and a national anatomic pathology provider, employing over 450 board-certified pathologists across 21+ practice locations in 16 states to deliver surgical pathology, cytopathology, dermatopathology, hematopathology, and molecular diagnostics to hospitals, ambulatory surgery centers, physician offices, and health plans.
- Ownership category
- akta.pro rank
AmeriPath industry classification
Industry- Product category
- Anatomic Pathology Services
- NAICS
- Medical and Diagnostic Laboratories (6215), Medical and Diagnostic Laboratories (62151)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro primary industry
- Anatomic Pathology (Histopathology & Cytopathology) (HLAFAMAA)
- akta.pro secondary industries
- Cytology & Histopathology Diagnostics (IHC, ISH, tissue-based assays) (HLAAALAI), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)
Keywords
Where AmeriPath is headquartered
LocationHeadquarters
- HQ city
- Palm Beach Gardens
- HQ country
- United States
- HQ region
- North America
Offices21 records
Markets served
AmeriPath business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Diagnostic Pathology Services: AmeriPath provides anatomic pathology services to hospitals, ambulatory surgery centers, and physician offices. Revenue is generated through professional fees for diagnostic services billed to health plans, Medicare, Medicaid, and directly to patients (self-pay).
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Self-pay pricing available upon request |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels3 records
AmeriPath product offering
Product offeringCore offering
AmeriPath provides anatomic pathology diagnostic services to hospitals, ambulatory surgery centers, and physician offices through a national network of over 450 board-certified pathologists and Ph.D.-level scientists. Its offerings span surgical pathology, cytopathology (including Pap smear screening), dermatopathology, hematopathology, and advanced molecular diagnostics such as BRCAvantage, Lynch Syndrome Panel, OncoVantage, Thyroid Molecular Panel, and Haystack MRD. The company also operates a Physician Web Portal for clinician case consultation and result access.
Product overview
AmeriPath is a leading national provider of anatomic pathology services offering a comprehensive diagnostic portfolio. The company provides core diagnostic services including Surgical Pathology, Cytopathology (with Pap smear testing), Dermatopathology, and Hematopathology. Their advanced molecular diagnostics portfolio includes BRCAvantage®, Lynch Syndrome Panel, OncoVantage™, and Thyroid Molecular Panel. Laboratory services encompass Immunohistochemistry (IHC), Histology, Special stains, Flow Cytometry, Cytogenetics, and molecular PCR/FISH/NGS testing. The company operates a Physician Web Portal for healthcare provider access. Specialized offerings include Haystack MRD™ for minimal residual disease detection. AmeriPath serves hospitals, ambulatory surgery centers, and physician offices through a network of over 450 board-certified pathologists, with clinical and advanced molecular testing menu offered through parent company Quest Diagnostics.
Differentiator
Problem solved
Functional benefit
Brands
- PhenoPath, PLLC: Dermatopathology services brand operating in Seattle, Washington.
Products and services
- Surgical Pathology Microscopic evaluation of tissue specimens removed during surgery to make definitive diagnoses of diseases including breast, prostate, skin, cervical, colon, and bone marrow biopsies, intended for hospitals, ambulatory surgery centers, and referring physicians.
- Cytopathology Evaluation of cells obtained from body fluids, solid tissues aspirated through needles, and body tissue scrapings, including Pap smears for cervical cancer screening, for hospitals, ambulatory surgery centers, and physician offices.
- Dermatopathology Pathology services specializing in diseases of the skin, including analysis of moles, rashes, and skin cancers, for dermatologists and referring physicians.
- Hematopathology Pathology services specializing in diseases of the blood and bone marrow, including leukemia and lymphoma diagnostics, for hematologists, oncologists, and hospitals.
- Molecular Diagnostics Advanced molecular testing panels including BRCAvantage, Lynch Syndrome Panel, OncoVantage, and Thyroid Molecular Panel for genetic and molecular disease detection, intended for oncologists, genetic counselors, and referring physicians.
- Haystack MRD Purpose-built, high-precision minimal residual disease (MRD) testing with exceptional detection sensitivity for cancer monitoring, intended for oncologists and cancer care programs.
- BRCAvantage Genetic testing panel for BRCA1 and BRCA2 gene mutations associated with hereditary breast and ovarian cancer risk, for oncologists, genetic counselors, and referring physicians.
- Lynch Syndrome Panel Genetic testing panel to identify Lynch syndrome, an inherited condition that increases cancer risk, for oncologists, gastroenterologists, and genetic counselors.
- OncoVantage Oncologic molecular testing panel for cancer diagnosis and treatment guidance, intended for oncologists and referring physicians.
- Thyroid Molecular Panel Molecular testing panel for thyroid nodule evaluation to determine likelihood of malignancy, for endocrinologists and referring physicians.
- Immunohistochemistry (IHC) Specialized staining technique using antibodies to detect specific proteins in tissue samples for diagnosis, for hospitals and anatomic pathology referral practices.
- Flow Cytometry Technique for analyzing cell characteristics used in hematopathology and cancer diagnostics, for hematologists, oncologists, and hospitals.
- Cytogenetics Analysis of chromosomes and genetic material for diagnosis of genetic disorders and cancer, for geneticists, oncologists, and referring physicians.
- Pap Smear / Pap Test Cervical cancer screening test involving microscopic examination of cells scraped from the cervix to detect abnormal changes, intended for gynecologists and primary care physicians.
- Chlamydia and Gonorrhea Testing Diagnostic testing for sexually transmitted infections caused by Chlamydia trachomatis and Neisseria gonorrhoeae bacteria, intended for hospitals, clinics, and referring physicians.
- Cystic Fibrosis Carrier Screening Prenatal carrier screening test to determine if individuals carry the cystic fibrosis gene mutation, for obstetricians, genetic counselors, and referring physicians.
- Physician Web Portal Online portal (webportal.ameripath.com) for healthcare providers to access case consultations, view results, and communicate with AmeriPath pathologists, intended for referring clinicians and practices.
Quantifiable outcome
- 24-48 hour turnaround time for most tissue and cytology evaluations
Companies that use AmeriPath
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles3 records
AmeriPath technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
AmeriPath partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Quest DiagnosticscoreQuest Diagnostics is the parent company of AmeriPath. Patients are redirected to Quest Diagnostics for billing payments and financial assistance. AmeriPath services are offered alongside Quest Diagnostics clinical and advanced molecular testing menu.
Scale indicators3 records
Recent moves1 record
Expansion highlights5 records
AmeriPath competitors and assessment
Company assessmentDirect peers
- PathGroup: U.S. physician-led anatomic and clinical pathology provider with a comprehensive molecular test menu and hospital/physician relationships; most similar regional-to-national anatomic pathology competitor to AmeriPath.
- NeoGenomics: Specialized oncology-focused clinical laboratory with a strong molecular and hematopathology practice; directly competes with AmeriPath for hospital and community oncology referrals in surgical pathology, IHC, FISH, NGS, and MRD.
- ARUP Laboratories: National reference laboratory affiliated with the University of Utah offering extensive anatomic pathology and esoteric testing; overlaps with AmeriPath's specialty menu and serves many of the same hospital clients.
- BioReference Laboratories (OPKO Health): Full-service clinical and anatomic pathology laboratory within OPKO Health; competes for hospital outreach, oncology, and urology pathology with comparable molecular and women's health testing panels.
Broad incumbents
- Quest Diagnostics: AmeriPath's parent company and the largest U.S. clinical reference lab; operates overlapping anatomic pathology services and shares the same molecular and MRD test menu, providing the most direct comparable for revenue model and scale.
- Mayo Clinic Laboratories: Reference laboratory operating within Mayo Clinic, offering deep subspecialty pathology and esoteric testing; competes with AmeriPath for tertiary hospital referrals and complex case volume.
- Sonic Healthcare USA: Global diagnostics operator with significant U.S. anatomic pathology presence via acquired labs; competes with AmeriPath in hospital-based and subspecialty pathology services across multiple regions.
- Labcorp: One of the largest U.S. clinical laboratory networks with a national anatomic pathology footprint and broad specialty/molecular menu; overlaps with AmeriPath across hospital and physician office channels and competes head-to-head for specialty diagnostic volume.
Emerging players
- Natera: Specialized molecular diagnostics company with strong oncology MRD and hereditary cancer franchises; an emerging competitor in the molecular and MRD segments where AmeriPath partners with Quest to compete.
- Caris Life Sciences: Emerging molecular oncology specialist with comprehensive tumor profiling and liquid biopsy offerings; competes at the high end of AmeriPath's molecular menu (BRCAvantage, OncoVantage, MRD).
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
AmeriPath social profiles
Digital presenceAmeriPath financial estimates
Financial estimateRevenue estimate
Valuation estimate
AmeriPath leadership team
Management profileNumber of profiles
Profiles15 records
AmeriPath subsidiaries and ownership
Company hierarchySubsidiaries21 records
AmeriPath funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AmeriPath M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AmeriPath
What does AmeriPath do?
AmeriPath provides anatomic pathology diagnostic services to hospitals, ambulatory surgery centers, and physician offices through a national network of over 450 board-certified pathologists and Ph.D.-level scientists. Its offerings span surgical pathology, cytopathology (including Pap smear screening), dermatopathology, hematopathology, and advanced molecular diagnostics such as BRCAvantage, Lynch Syndrome Panel, OncoVantage, Thyroid Molecular Panel, and Haystack MRD. The company also operates a Physician Web Portal for clinician case consultation and result access.
Is AmeriPath a public or private company?
AmeriPath is a private company. It is classified as corporate owned and is currently operating.
When was AmeriPath founded?
AmeriPath was founded in 1996. It employs 5,001 to 10,000 people.
Where is AmeriPath based?
AmeriPath is headquartered in Palm Beach Gardens, United States, in the North America region.
How does AmeriPath make money?
One revenue line is on record: diagnostic Pathology Services.
Who are AmeriPath's main competitors?
Direct peers on record are PathGroup, NeoGenomics, ARUP Laboratories and BioReference Laboratories (OPKO Health). Broad incumbents are Quest Diagnostics, Mayo Clinic Laboratories, Sonic Healthcare USA and Labcorp. Emerging players are Natera and Caris Life Sciences.
Does AmeriPath have an API?
No public API is recorded for AmeriPath.
What industry is AmeriPath in?
AmeriPath's product category is Anatomic Pathology Services. Its primary akta.pro industry code is HLAFAMAA, Anatomic Pathology (Histopathology & Cytopathology), with a secondary code of HLAAALAI, Cytology & Histopathology Diagnostics (IHC, ISH, tissue-based assays). Its NAICS code is 6215 and its SIC code is 8071.